Yesterday was all about Eliquis. First up were the patient listening sessions I keep prattling on about. And while there was some sense that the parade of speakers didn’t shed
Below are transcripts (PDF) for all of the speakers at the CMS patient-focused listening sessions. Where possible, we've provided affiliations. CMS refers to speakers only with their first name, so
I’m on the road this week, which means I had the pleasure of overhearing a woman explaining the concept of a “beer back” to the patron sitting next to her
I don’t think there is a whole lot of analysis needed on the Commonwealth Fund’s look at the impact of high health care costs on consumers. A majority of the
Near-Term Programming Note: Cost Curve is off tomorrow, back Friday for AbbVie earnings and whatever other fun befalls us in the next 48 hours. Long-Term Programming Note: I plan to
The Arc It’s a slow day today, so this is a brief Arc to prematurely flag an interesting trend: we’re a week or into pharma earnings season, and while
Inflection Point Inflection Point is usually for big, driving-the-day kind of news. So a story about the fact that the net price of obesity medicines being a ton lower
Inflection Point If you’re into the IRA, it’s worth carving out a few minutes today to read this white paper from Avalere on the development path of cardiovascular medicines and
Hoo boy: there is a lot to unpack today. Let’s get started. Inflection Point There may be no single document that is more useful for understanding where the U.S.
Inflection Point It’s not clear to me that anyone has noticed, but the government weighed in last night on the lawsuits from Johnson & Johnson and BMS challenging the